The Emerging Issue of Cardiac Dysfunction Induced by Antineoplastic Angiogenesis InhibitorsCarlo G. Tocchetti, Nicola Maurea, Carmela Coppola et al.|European Journal of Heart Failure|2013Cited by 70
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Gennaro Riccio, Nicola Maurea, Carmela Coppola et al.|Human Vaccines & Immunotherapeutics|2016Cited by 55
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS ProductionGennaro Riccio, Nicola Maurea, Salvatore Antonucci et al.|Frontiers in Physiology|2018Cited by 51
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in CardioncologyVincenzo Quagliariello, Nicola Maurea, Irma Bisceglia et al.|Cancers|2023Cited by 42
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle trackingCarmela Coppola, Nicola Maurea, Gennaro Riccio et al.|OncoTargets and Therapy|2016Cited by 34